Smoking Cessation at Lung Examination (Part 1): Findings and Lessons Learned from the NCI SCALE Collaboration Webinar

Webinar | English | 2025 | 60 Min

Create Account

Availability

On-Demand

Cost

$0.00

Credit Offered

1 Certificate of Attendance Credit

The U.S. Preventive Services Task Force recommends lung cancer screening (LCS) with low-dose computed tomography for adults aged 50 to 80 years who have smoked 20+ pack years and currently smoke or have quit within the past 15 years. LCS may be a teachable moment and an opportunity to deliver tobacco cessation treatment; however, how best to integrate high-quality tobacco cessation treatment into the LCS context is uncertain.

The Smoking Cessation at Lung Examination (SCALE) Collaboration was created to accelerate understanding of the implementation and effectiveness of smoking cessation interventions in the context of LCS by supporting cross-project research across 8 funded randomized controlled clinical trials. This 2-part webinar series will discuss the findings and lessons learned from this initiative.

This activity is designed to meet the educational needs of researchers and healthcare professionals who diagnose and treat patients with lung cancer including medical oncologists, thoracic surgeons, radiation oncologists, radiologists, pathologists, advanced practice nurses and physician assistants.

Upon completion of this activity, the participants should be able to:

Describe several investigational SCALE Collaboration smoking cessation interventions in the context of lung cancer screening.
Develop and increase insight into the implementation and effectiveness of the delivery of tobacco cessation treatments in varied lung cancer screening clinical contexts.
Examine best practices and implications associated with the delivery of tobacco cessation treatments in the context of lung cancer screening.

Moderator:

Benjamin Toll, PhD, Professor and Vice Chair, The Medical University of South Carolina, Charleston, SC, USA

Presenters:

Abbie Begnaud, MD, Associate Professor, University of Minnesota, Minneapolis, MN, USA
Scott Coggeshall, PhD, Biostatistician, VA Puget Sound, Seattle, WA, USA
Kristie Foley, PhD, MS, Professor and Chair, Wake Forest University School of Medicine, Winston-Salem, NC, USA
Jennifer Minnix, PhD, Assistant Professor, UT MD Anderson Cancer Center, Houston, TX, USA
Jamie Ostroff, PhD, Founder and Director, Tobacco Cessation Program, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
Elyse Park, PhD, Director of Behavioral Sciences, Associate Professor, Harvard Medical School, Boston, MA, USA
Randi Williams, PhD, Assistant Professor, Georgetown University, Washington, D.C., USA

The information presented is that of the contributing faculty and does not necessarily represent the views of the International Association for the Study of Lung Cancer and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty presenters. Therefore, before prescribing any medication, please review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse effects.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

If you need any assistance with this activity, please email: education@iaslc.org.